|
|
|
|
LEADER |
05022nam a2201129Ia 4500 |
001 |
10-1182-blood-2021012806 |
008 |
220420s2022 CNT 000 0 und d |
020 |
|
|
|a 00064971 (ISSN)
|
245 |
1 |
0 |
|a The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
|
260 |
|
0 |
|b Elsevier B.V.
|c 2022
|
300 |
|
|
|a 13
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1182/blood.2021012806
|
520 |
3 |
|
|a Translocations involving the NUP98 gene produce NUP98-fusion proteins and are associated with a poor prognosis in acute myeloid leukemia (AML). MLL1 is a molecular dependency in NUP98-fusion leukemia, and therefore we investigated the efficacy of therapeutic blockade of the menin-MLL1 interaction in NUP98-fusion leukemia models. Using mouse leukemia cell lines driven by NUP98-HOXA9 and NUP98-JARID1A fusion oncoproteins, we demonstrate that NUP98-fusion-driven leukemia is sensitive to the menin-MLL1 inhibitor VTP50469, with an IC50 similar to what we have previously reported for MLL-rearranged and NPM1c leukemia cells. Menin-MLL1 inhibition upregulates markers of differentiation such as CD11b and downregulates expression of proleukemogenic transcription factors such as Meis1 in NUP98-fusion-transformed leukemia cells. We demonstrate that MLL1 and the NUP98 fusion protein itself are evicted from chromatin at a critical set of genes that are essential for the maintenance of the malignant phenotype. In addition to these in vitro studies, we established patient-derived xenograft (PDX) models of NUP98-fusion-driven AML to test the in vivo efficacy of menin-MLL1 inhibition. Treatment with VTP50469 significantly prolongs survival of mice engrafted with NUP98-NSD1 and NUP98-JARID1A leukemias. Gene expression analysis revealed that menin-MLL1 inhibition simultaneously suppresses a proleukemogenic gene expression program, including downregulation of the HOXa cluster, and upregulates tissue-specific markers of differentiation. These preclinical results suggest that menin-MLL1 inhibition may represent a rational, targeted therapy for patients with NUP98-rearranged leukemias. © 2022 American Society of Hematology
|
650 |
0 |
4 |
|a acute myeloid leukemia
|
650 |
0 |
4 |
|a acute myeloid leukemia
|
650 |
0 |
4 |
|a animal
|
650 |
0 |
4 |
|a animal cell
|
650 |
0 |
4 |
|a animal experiment
|
650 |
0 |
4 |
|a animal model
|
650 |
0 |
4 |
|a animal tissue
|
650 |
0 |
4 |
|a Animals
|
650 |
0 |
4 |
|a antineoplastic agent
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a C57BL mouse
|
650 |
0 |
4 |
|a cancer survival
|
650 |
0 |
4 |
|a CD11b antigen
|
650 |
0 |
4 |
|a Cell Line, Tumor
|
650 |
0 |
4 |
|a chromatin
|
650 |
0 |
4 |
|a controlled study
|
650 |
0 |
4 |
|a down regulation
|
650 |
0 |
4 |
|a fusion protein
|
650 |
0 |
4 |
|a gene cluster
|
650 |
0 |
4 |
|a gene expression
|
650 |
0 |
4 |
|a gene expression profiling
|
650 |
0 |
4 |
|a gene expression regulation
|
650 |
0 |
4 |
|a Gene Expression Regulation, Leukemic
|
650 |
0 |
4 |
|a gene rearrangement
|
650 |
0 |
4 |
|a gene rearrangement
|
650 |
0 |
4 |
|a Gene Rearrangement
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a histone lysine methyltransferase
|
650 |
0 |
4 |
|a Histone-Lysine N-Methyltransferase
|
650 |
0 |
4 |
|a IC50
|
650 |
0 |
4 |
|a in vitro study
|
650 |
0 |
4 |
|a in vivo study
|
650 |
0 |
4 |
|a Kmt2a protein, mouse
|
650 |
0 |
4 |
|a leukemia cell line
|
650 |
0 |
4 |
|a Leukemia, Myeloid, Acute
|
650 |
0 |
4 |
|a Men1 protein, mouse
|
650 |
0 |
4 |
|a metabolism
|
650 |
0 |
4 |
|a methionine
|
650 |
0 |
4 |
|a Mice
|
650 |
0 |
4 |
|a Mice, Inbred C57BL
|
650 |
0 |
4 |
|a mixed lineage leukemia protein
|
650 |
0 |
4 |
|a mixed lineage leukemia protein
|
650 |
0 |
4 |
|a mouse
|
650 |
0 |
4 |
|a murine leukemia
|
650 |
0 |
4 |
|a Myeloid-Lymphoid Leukemia Protein
|
650 |
0 |
4 |
|a nonhuman
|
650 |
0 |
4 |
|a nuclear pore complex protein 98
|
650 |
0 |
4 |
|a Nuclear Pore Complex Proteins
|
650 |
0 |
4 |
|a nucleoporin
|
650 |
0 |
4 |
|a nucleoporin 98
|
650 |
0 |
4 |
|a nup98 gene
|
650 |
0 |
4 |
|a oncogene
|
650 |
0 |
4 |
|a Oncogene Proteins, Fusion
|
650 |
0 |
4 |
|a oncoprotein
|
650 |
0 |
4 |
|a phenotype
|
650 |
0 |
4 |
|a protein analysis
|
650 |
0 |
4 |
|a Protein Interaction Maps
|
650 |
0 |
4 |
|a protein protein interaction
|
650 |
0 |
4 |
|a Proto-Oncogene Proteins
|
650 |
0 |
4 |
|a retinoblastoma binding protein 2
|
650 |
0 |
4 |
|a transcription factor HoxA9
|
650 |
0 |
4 |
|a tumor cell line
|
650 |
0 |
4 |
|a tumor xenograft
|
650 |
0 |
4 |
|a unclassified drug
|
650 |
0 |
4 |
|a upregulation
|
650 |
0 |
4 |
|a vtp 50469
|
700 |
1 |
0 |
|a Armstrong, S.A.
|e author
|
700 |
1 |
0 |
|a Barwe, S.P.
|e author
|
700 |
1 |
0 |
|a Gopalakrishnapillai, A.
|e author
|
700 |
1 |
0 |
|a Hatton, C.
|e author
|
700 |
1 |
0 |
|a Heikamp, E.B.
|e author
|
700 |
1 |
0 |
|a Henrich, J.A.
|e author
|
700 |
1 |
0 |
|a Kazansky, Y.
|e author
|
700 |
1 |
0 |
|a Kentsis, A.
|e author
|
700 |
1 |
0 |
|a Kolb, E.A.
|e author
|
700 |
1 |
0 |
|a McGeehan, G.M.
|e author
|
700 |
1 |
0 |
|a Perner, F.
|e author
|
700 |
1 |
0 |
|a Pikman, Y.
|e author
|
700 |
1 |
0 |
|a Takao, S.
|e author
|
700 |
1 |
0 |
|a Uckelmann, H.J.
|e author
|
700 |
1 |
0 |
|a Wen, Y.
|e author
|
700 |
1 |
0 |
|a Wong, E.M.
|e author
|
700 |
1 |
0 |
|a Xu, H.
|e author
|
773 |
|
|
|t Blood
|